Triazoles Versus Echinocandins for the First-Line Treatment of Invasive Pulmonary Aspergillosis: A Propensity Score–Weighted Multicenter Study
Using echinocandins as alternative first-line treatment for IPA may result in poorer survival outcomes and should be approached with caution until further trials confirm our findings.
Authors
- Robert Krause (ORCID: https://orcid.org/0000-0001-6656-3648)
- Dirk von Lewinski (ORCID: https://orcid.org/0000-0001-9996-6128)
- Markus Keldorfer
- Lisa Kriegl (ORCID: https://orcid.org/0000-0002-1977-2196)
- Andreas Reinisch (ORCID: https://orcid.org/0000-0001-9333-7689)
- Christina Geiger (ORCID: https://orcid.org/0000-0003-4918-1749)
- Stefan Hatzl (ORCID: https://orcid.org/0000-0001-6266-0512)
- Markus Wallner (ORCID: https://orcid.org/0000-0001-7692-892X)
- Albert Wölfler (ORCID: https://orcid.org/0000-0002-3112-9857)
- Philipp Eller (ORCID: https://orcid.org/0000-0001-5537-3646)
Institutions
- Medical University of Graz (AT)
- BioTechMed-Graz (AT)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1093/ofid/ofaf709
- Citations
- 2
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Pfizer